Aspirin may alter fallopian tubes, early study hints at cancer prevention
NCT ID NCT03771651
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether taking a low dose of aspirin daily for two weeks before surgery can change the immune environment of the fallopian tubes. Researchers will compare tissue from 18 women who take aspirin to control samples, looking for signs of reduced inflammation and lower cancer-related changes. The goal is to understand if aspirin could one day help prevent fallopian tube cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin 81 mg
What this could lead to
If successful, this could point toward a simple, low-cost way to reduce fallopian tube inflammation and potentially lower cancer risk.
What could go wrong
This is a very early, small pilot study with only 18 participants. It looks at biological changes, not actual cancer prevention, so results may not lead to a proven treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117, United States